 Jeffrey SooHoo
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 19 | 2025 | 253 | 3.770 |
Why?
| | Intraocular Pressure | 27 | 2025 | 332 | 2.490 |
Why?
| | Phacoemulsification | 12 | 2025 | 123 | 1.750 |
Why?
| | Angiogenesis Inhibitors | 4 | 2018 | 239 | 1.570 |
Why?
| | Trabeculectomy | 10 | 2025 | 75 | 1.540 |
Why?
| | Glaucoma Drainage Implants | 5 | 2021 | 47 | 1.390 |
Why?
| | Glaucoma, Open-Angle | 8 | 2023 | 105 | 1.330 |
Why?
| | Filtering Surgery | 5 | 2016 | 23 | 1.120 |
Why?
| | Glaucoma, Neovascular | 2 | 2015 | 10 | 0.830 |
Why?
| | Trabecular Meshwork | 5 | 2019 | 74 | 0.790 |
Why?
| | Tonometry, Ocular | 10 | 2025 | 104 | 0.780 |
Why?
| | Lens Implantation, Intraocular | 4 | 2018 | 80 | 0.750 |
Why?
| | Microfluidic Analytical Techniques | 2 | 2012 | 79 | 0.610 |
Why?
| | Laser Coagulation | 5 | 2025 | 80 | 0.580 |
Why?
| | Eye Injuries | 2 | 2021 | 53 | 0.540 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2015 | 552 | 0.500 |
Why?
| | Cell Separation | 2 | 2009 | 306 | 0.500 |
Why?
| | Leukocytes | 2 | 2009 | 301 | 0.470 |
Why?
| | Cataract | 6 | 2023 | 238 | 0.460 |
Why?
| | Ciliary Body | 3 | 2025 | 40 | 0.460 |
Why?
| | Perception | 1 | 2018 | 378 | 0.440 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 109 | 0.430 |
Why?
| | Laser Therapy | 2 | 2016 | 146 | 0.430 |
Why?
| | Antihypertensive Agents | 2 | 2016 | 522 | 0.430 |
Why?
| | Prosthesis Design | 1 | 2016 | 363 | 0.420 |
Why?
| | Ocular Hypertension | 3 | 2022 | 71 | 0.410 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2015 | 192 | 0.410 |
Why?
| | Blepharoptosis | 1 | 2014 | 13 | 0.410 |
Why?
| | Hyphema | 1 | 2013 | 7 | 0.400 |
Why?
| | Visual Acuity | 6 | 2025 | 498 | 0.400 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 91 | 0.400 |
Why?
| | Telangiectasis | 1 | 2013 | 7 | 0.390 |
Why?
| | Skin Diseases, Vascular | 1 | 2013 | 8 | 0.390 |
Why?
| | Patient Preference | 1 | 2016 | 225 | 0.390 |
Why?
| | Endoscopy | 3 | 2025 | 322 | 0.380 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 669 | 0.360 |
Why?
| | Orbital Neoplasms | 1 | 2012 | 28 | 0.360 |
Why?
| | Ophthalmologists | 2 | 2023 | 21 | 0.360 |
Why?
| | Anterior Chamber | 1 | 2012 | 26 | 0.360 |
Why?
| | Fluorescein Angiography | 1 | 2013 | 195 | 0.350 |
Why?
| | Conjunctiva | 1 | 2012 | 52 | 0.350 |
Why?
| | Intravitreal Injections | 3 | 2018 | 73 | 0.340 |
Why?
| | Carcinoma | 1 | 2012 | 231 | 0.320 |
Why?
| | Dexamethasone | 1 | 2012 | 368 | 0.300 |
Why?
| | Stents | 4 | 2021 | 570 | 0.300 |
Why?
| | Uveitis | 2 | 2022 | 151 | 0.300 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2012 | 261 | 0.300 |
Why?
| | Blood Component Removal | 1 | 2009 | 26 | 0.290 |
Why?
| | Cataract Extraction | 2 | 2023 | 120 | 0.280 |
Why?
| | Ophthalmic Solutions | 3 | 2018 | 82 | 0.270 |
Why?
| | Humans | 43 | 2025 | 147306 | 0.270 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 6164 | 0.270 |
Why?
| | Ultrafiltration | 1 | 2007 | 28 | 0.250 |
Why?
| | Microfluidics | 1 | 2007 | 61 | 0.240 |
Why?
| | Leukocyte Count | 1 | 2007 | 319 | 0.230 |
Why?
| | Erythrocytes | 1 | 2012 | 749 | 0.230 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.220 |
Why?
| | Prosthesis Implantation | 2 | 2018 | 156 | 0.200 |
Why?
| | Negotiating | 1 | 2023 | 34 | 0.190 |
Why?
| | Mentoring | 1 | 2025 | 166 | 0.180 |
Why?
| | Aged | 13 | 2025 | 26516 | 0.170 |
Why?
| | Ophthalmology | 1 | 2023 | 121 | 0.170 |
Why?
| | Internship and Residency | 2 | 2023 | 1279 | 0.170 |
Why?
| | Weapons | 1 | 2021 | 8 | 0.170 |
Why?
| | Treatment Outcome | 8 | 2025 | 11947 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.160 |
Why?
| | Students, Medical | 1 | 2025 | 380 | 0.160 |
Why?
| | Female | 18 | 2025 | 80081 | 0.150 |
Why?
| | Equipment Design | 3 | 2018 | 527 | 0.150 |
Why?
| | Retrospective Studies | 12 | 2025 | 17561 | 0.150 |
Why?
| | Aged, 80 and over | 7 | 2025 | 8432 | 0.150 |
Why?
| | Postoperative Period | 4 | 2025 | 351 | 0.150 |
Why?
| | Male | 18 | 2025 | 73954 | 0.150 |
Why?
| | Education, Medical, Graduate | 2 | 2023 | 568 | 0.150 |
Why?
| | Administration, Topical | 2 | 2016 | 156 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2025 | 490 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.130 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 27 | 0.130 |
Why?
| | Equipment Failure Analysis | 2 | 2009 | 124 | 0.130 |
Why?
| | Middle Aged | 11 | 2025 | 36821 | 0.130 |
Why?
| | Adult | 11 | 2025 | 41406 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2025 | 5478 | 0.130 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.120 |
Why?
| | Acrylic Resins | 1 | 2016 | 48 | 0.120 |
Why?
| | Lenses, Intraocular | 1 | 2016 | 49 | 0.120 |
Why?
| | Cadaver | 1 | 2016 | 316 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 6011 | 0.110 |
Why?
| | Infant | 4 | 2014 | 10195 | 0.110 |
Why?
| | Drug Packaging | 1 | 2015 | 41 | 0.110 |
Why?
| | Vision Disorders | 1 | 2016 | 179 | 0.110 |
Why?
| | Blepharoplasty | 1 | 2014 | 9 | 0.100 |
Why?
| | Rabbits | 2 | 2012 | 654 | 0.100 |
Why?
| | Young Adult | 4 | 2025 | 14437 | 0.100 |
Why?
| | Eyelids | 1 | 2014 | 41 | 0.100 |
Why?
| | Accidents, Home | 1 | 2013 | 33 | 0.100 |
Why?
| | Livedo Reticularis | 1 | 2013 | 4 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 951 | 0.100 |
Why?
| | Iris | 1 | 2013 | 23 | 0.100 |
Why?
| | Oculomotor Muscles | 1 | 2014 | 86 | 0.090 |
Why?
| | Prospective Studies | 4 | 2021 | 8166 | 0.090 |
Why?
| | Sulfonamides | 1 | 2016 | 596 | 0.090 |
Why?
| | Urothelium | 1 | 2012 | 33 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1912 | 0.090 |
Why?
| | Goblet Cells | 1 | 2012 | 22 | 0.090 |
Why?
| | Mitomycin | 1 | 2012 | 33 | 0.090 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2012 | 50 | 0.090 |
Why?
| | Blister | 1 | 2012 | 39 | 0.090 |
Why?
| | Diffusion | 1 | 2012 | 120 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2012 | 306 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 287 | 0.080 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 191 | 0.080 |
Why?
| | Medication Adherence | 1 | 2015 | 540 | 0.080 |
Why?
| | Hemolysis | 1 | 2012 | 242 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 460 | 0.070 |
Why?
| | Phase Transition | 1 | 2009 | 25 | 0.070 |
Why?
| | Wound Healing | 1 | 2012 | 361 | 0.070 |
Why?
| | Adolescent | 4 | 2019 | 22826 | 0.070 |
Why?
| | Kinetics | 1 | 2012 | 1569 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2021 | 3022 | 0.070 |
Why?
| | Postoperative Care | 2 | 2025 | 299 | 0.060 |
Why?
| | Incidence | 1 | 2013 | 2954 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2921 | 0.060 |
Why?
| | Sex Factors | 2 | 2023 | 2136 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3784 | 0.050 |
Why?
| | Colorado | 1 | 2013 | 4591 | 0.050 |
Why?
| | Salaries and Fringe Benefits | 1 | 2023 | 58 | 0.050 |
Why?
| | Empathy | 1 | 2025 | 184 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2014 | 6543 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2791 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.040 |
Why?
| | Internet | 1 | 2025 | 696 | 0.040 |
Why?
| | Child, Preschool | 2 | 2013 | 12017 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2007 | 4170 | 0.040 |
Why?
| | Health Surveys | 1 | 2021 | 522 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 150 | 0.030 |
Why?
| | Educational Status | 1 | 2020 | 475 | 0.030 |
Why?
| | Axial Length, Eye | 1 | 2018 | 16 | 0.030 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Histological Techniques | 1 | 2018 | 39 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2023 | 514 | 0.030 |
Why?
| | Pseudophakia | 1 | 2018 | 21 | 0.030 |
Why?
| | Refraction, Ocular | 1 | 2018 | 47 | 0.030 |
Why?
| | Microscopy | 1 | 2018 | 148 | 0.030 |
Why?
| | Physicians | 1 | 2025 | 961 | 0.030 |
Why?
| | Curriculum | 1 | 2023 | 1083 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 568 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 895 | 0.030 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 10 | 0.030 |
Why?
| | Clinical Competence | 1 | 2023 | 1260 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 85 | 0.030 |
Why?
| | Child | 2 | 2013 | 22980 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 290 | 0.030 |
Why?
| | United States | 2 | 2023 | 16313 | 0.030 |
Why?
| | Animals | 2 | 2012 | 38417 | 0.020 |
Why?
| | Tissue Donors | 1 | 2012 | 427 | 0.020 |
Why?
| | Neoplasms | 1 | 1975 | 2946 | 0.010 |
Why?
| | Mexico | 1 | 1975 | 233 | 0.010 |
Why?
| | Emigration and Immigration | 1 | 1975 | 67 | 0.010 |
Why?
| | California | 1 | 1975 | 477 | 0.010 |
Why?
| | Risk | 1 | 1975 | 927 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1975 | 268 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 1975 | 2420 | 0.000 |
Why?
| | Lung Neoplasms | 1 | 1975 | 2679 | 0.000 |
Why?
|
|
SooHoo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|